Author

H. Asakura

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 14 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 14 Organism:human· 11 Approach:experimental assay· 9 Approach:statistical model· 5 Organism:virus· 3 Approach:comparative / phylogenetic analysis· 2 Assay:proteomics· 2 Organism:bacteria (other)· 1

Frequent Co-Authors

J. Ito· 12 shared K. Sadamasu· 12 shared K. Uriu· 12 shared K. Yoshimura· 12 shared The Genotype to Phenotype Japan (G2P-Japan) Consortium· 12 shared M. Nagashima· 11 shared Y. Kosugi· 10 shared H. Nasser· 9 shared

Activity by Year

2020-2024 · peak 6/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

12 shared papersMicrobiology

J. Ito

Mutual co-authors in cluster

Author profile →

15 papers

Recent·Most cited

Virological characteristics of the SARS-CoV-2 KP.2 variant

Y. Kaku, K. Uriu, Y. Kosugi, K. Okumura, D. Yamasoba, Y. Uwamino, J. Kuramochi, K. Sadamasu, K. Yoshimura, M. Nagashima, H. Asakura, The Genotype to Phenotype Japan (G2P-Japan) Consortium, J. Ito, K. Sato

This study investigates the virological properties of the SARS-CoV-2 KP.2 variant, finding it has higher viral fitness and immune resistance compared to JN.1, contributing to its rapid spread.

The Lancet Infectious Diseases · Jul 1, 2024Peer-reviewedMicrobiology

Virological characteristics of the SARS-CoV-2 Omicron HK.3 variant harboring the "FLip" substitution

Y. Kosugi, A. Plianchaisuk, O. Putri, K. Uriu, Y. Kaku, A. A. Hinay, L. Chen, J. Kuramochi, K. Sadamasu, K. Yoshimura, H. Asakura, M. Nagashima, The Genotype to Phenotype Japan (G2P-Japan) Consortium, J. Ito, K. Sato

This study investigates the virological properties of the SARS-CoV-2 HK.3 variant, a FLip variant with substitutions S:L455F and S:F456L, to assess its growth advantage.

bioRxiv · Nov 14, 2023 · PreprintMicrobiology

Virological characteristics of the SARS-CoV-2 BA.2.86 variant

T. Tamura, K. Mizuma, H. Nasser, S. Deguchi, M. Padilla-Blanco, K. Uriu, J. E. M. Tolentino, S. Tsujino, R. Suzuki, I. Kojima, N. Nao, R. Shimizu, M. Jonathan, Y. Kosugi, Z. Guo, , K. Sato

This study investigates the virological characteristics of the SARS-CoV-2 BA.2.86 variant, finding it has higher reproduction number than EG.5.1 but lower pathogenicity and replication capacity compared to BA.2.

bioRxiv · Nov 2, 2023Microbiology

Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant

S. Tsujino, S. Deguchi, T. Nomai, M. Padilla-Blanco, A. Plianchaisuk, L. Wang, M. M. Begum, K. Uriu, K. Mizuma, N. Nao, I. Kojima, T. Tsubo, J. Li, Y. Matsumura, M. Nagao, , Za

The paper investigates the virological features of the SARS-CoV-2 EG.5.1 variant, finding its fitness and antiviral sensitivity comparable to XBB.1.5, with structural differences in spike proteins.

bioRxiv · Oct 19, 2023Microbiology

Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against Omicron subvariants including EG.5

Y. Kaku, Y. Kosugi, K. Uriu, J. Ito, J. Kuramochi, K. Sadamasu, K. Yoshimura, H. Asakura, M. Nagashima, The Genotype to Phenotype Japan (G2P-Japan) Consortium, K. Sato

This study evaluates the antiviral efficacy of XBB breakthrough infection sera against EG.5.1 and other Omicron subvariants, finding comparable neutralization titers and suggesting immune evasion is not the main driver of EG.5.1's spread.

bioRxiv · Aug 8, 2023 · PreprintMicrobiology

Contrasting genes conferring short and long-term biofilm adaptation in Listeria

W. Monteith, B. Pascoe, E. Mourkas, J. L. Clark, M. Hakim, M. D. Hitchings, N. McCarthy, K. Yahara, H. Asakura, S. Sheppard

This study identifies 273 genes associated with biofilm formation in Listeria monocytogenes through GWAS and 220 genes through RNAseq, finding fewer overlaps than expected, suggesting distinct evolutionary adaptation mechanisms.

bioRxiv · Jun 22, 2023 · PreprintMicrobiology

Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants

T. Tamura, J. Ito, K. Uriu, J. Zahradnik, I. Kida, H. Nasser, M. Shofa, Y. Oda, S. Lytras, N. Nao, Y. Itakura, S. Deguchi, R. Suzuki, L. Wang, M. M. Begum, , K. Sato

This study identifies XBB as a SARS-CoV-2 variant resulting from recombination of BA.2 subvariants, showing increased resistance to neutralizing antibodies and enhanced fusogenicity compared to BA.2.75.

bioRxiv · Dec 27, 2022 · PreprintMicrobiology

Convergent evolution of the SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant

J. Ito, R. Suzuki, K. Uriu, Y. Itakura, J. Zahradnik, S. Deguchi, L. Wang, S. Lytras, T. Tamura, I. Kida, H. Nasser, M. Shofa, M. M. Begum, M. Tsuda, Y. Oda, , K. Sato

The paper investigates convergent evolution in SARS-CoV-2 Omicron subvariants, identifying five critical spike protein substitutions in BQ.1.1 that enhance viral fitness and antibody resistance.

bioRxiv · Dec 5, 2022Microbiology

Virological characteristics of the SARS-CoV-2 Omicron BA.2.75

A. Saito, T. Tamura, J. Zahradnik, S. Deguchi, K. Tabata, I. Kimura, J. Ito, H. Nasser, M. Toyoda, K. Nagata, K. Uriu, Y. Kosugi, S. Fujita, D. Yamasoba, M. Shofa, , Kei Sato

This study investigates the virological characteristics of SARS-CoV-2 Omicron BA.2.75, finding it has higher transmissibility and pathogenicity compared to BA.2 and BA.5, but similar sensitivity to antiviral drugs.

bioRxiv · Jul 14, 2022Microbiology

Virological characteristics of the novel SARS-CoV-2 Omicron variants including BA.2.12.1, BA.4 and BA.5

I. Kimura, D. Yamasoba, T. Tamura, N. Nao, Y. Oda, S. Mitoma, J. Ito, H. Nasser, J. Zahradnik, K. Uriu, S. Fujita, Y. Kosugi, L. Wang, M. Tsuda, M. Kishimoto, , K. Sato

This study analyzes the virological characteristics of SARS-CoV-2 Omicron variants BA.2.12.1, BA.4, and BA.5, finding they have higher reproduction numbers, reduced neutralization by prior immunity, increased replication in lung cells, and greater pathogenicity in hamsters compared to BA.2.

bioRxiv · May 26, 2022Microbiology

SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant

I. Kimura, D. Yamasoba, H. Nasser, J. Zahradnik, Y. Kosugi, J. Wu, K. Nagata, K. Uriu, Y. L. Tanaka, J. Ito, R. Shimizu, T. S. Tan, E. P. Butlertanaka, H. Asakura, K. Sadamasu, , K. Sato

This study identifies the S375F mutation in the Omicron spike protein as responsible for its reduced cleavage efficiency, fusogenicity, and rapid spread.

bioRxiv · Apr 3, 2022Microbiology

Virological characteristics of SARS-CoV-2 BA.2 variant

D. Yamasoba, I. Kimura, H. Nasser, Y. Morioka, N. Nao, J. Ito, K. Uriu, M. Tsuda, J. Zahradnik, K. Shirakawa, R. Suzuki, M. Kishimoto, Y. Kosugi, K. Kobiyama, T. Hara, , Sawa

This study compares the virological characteristics of SARS-CoV-2 BA.2 and BA.1 variants, finding BA.2 has higher transmissibility, different antigenicity, greater replicative capacity, and higher pathogenicity in hamsters.

bioRxiv · Feb 14, 2022Microbiology

SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant, enhances viral fusogenicity and pathogenicity

A. Saito, T. Irie, R. Suzuki, T. Maemura, H. Nasser, K. Uriu, Y. Kosugi, K. Shirakawa, K. Sadamasu, I. Kimura, J. Ito, J. Wu, K. Iwatsuki-Horimoto, M. Ito, S. Yamayoshi, , K. Sato

This study shows the P681R mutation in the SARS-CoV-2 spike protein enhances fusogenicity and pathogenicity in the Delta variant compared to the prototypic virus.

bioRxiv · Jun 17, 2021Microbiology

Clomipramine suppresses ACE2-mediated SARS-CoV-2 entry

Y. Kato, S. Yamada, K. Nishiyama, A. Satsuka, S. Re, D. Tomokiyo, J. M. Lee, T. Tanaka, A. Nishimura, K. Yonemitsu, H. Asakura, Y. Ibuki, Y. Imai, N. Kamiya, K. Mizuguchi, , M. Nishida

This study shows clomipramine inhibits SARS-CoV-2 entry into cardiomyocytes and synergizes with remdesivir to suppress infection.

bioRxiv · Mar 13, 2021 · PreprintPharmacology & Toxicology

Photocatalyst under visible light irradiation inactivates SARS-CoV-2 on an abiotic surface

M. Uema, K. Yonemitsu, Y. Momose, Y. Ishii, K. Tateda, T. Inoue, H. Asakura

This study shows that a visible light-responsive photocatalyst inactivates SARS-CoV-2 on surfaces under specific conditions, reducing viral titers and spike protein levels.

bioRxiv · Nov 1, 2020 · PreprintMicrobiology